Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.